Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 8/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | C5AR1 | P21730 | 5/20 | 0.35 |
| ▸ | F12 | P00748 | 2/20 | 0.35 |
| ▸ | HTR5A | P47898 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21175373 | 0.88 | DPP4 (0.39) | DPP4DPP7DPP8DPP9C5AR1 | |
| SCHEMBL29475107 | 0.86 | F12 (0.50) | DPP4DPP7DPP8DPP9C5AR1 | |
| SCHEMBL20015371 | 0.86 | F12 (0.50) | DPP4DPP7DPP8DPP9C5AR1 | |
| SCHEMBL21175127 | 0.83 | F12 (0.35) | DPP4DPP7DPP8DPP9C5AR1 | |
| SCHEMBL21175427 | 0.82 | F12 (0.37) | DPP4DPP7DPP8DPP9C5AR1 | |
| SCHEMBL27254706 | 0.81 | DPP4 (0.36) | DPP4DPP7DPP8DPP9ENPP2 | |
| SCHEMBL21175380 | 0.80 | DPP4 (0.39) | DPP4DPP7DPP8DPP9ENPP2 | |
| SCHEMBL21175390 | 0.77 | ENPP2 (0.35) | DPP4DPP7DPP8DPP9ENPP2 | |
| SCHEMBL21175154 | 0.76 | NTRK1 (0.41) | DPP4DPP7DPP8DPP9ENPP2 | |
| SCHEMBL28379944 | 0.72 | C5AR1 (0.48) | C5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4349840-A2 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-10 | — | — | EP | disclosed |
| EP-3517538-B1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2024-03-13 | — | — | EP | disclosed |
| US-20230382912-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-30 | — | — | US | disclosed |
| US-11814381-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-14 | — | — | US | disclosed |
| EP-4134367-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-02-15 | — | — | EP | disclosed |
| US-20210017176-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-01-21 | — | — | US | disclosed |
| US-10858356-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-12-08 | — | — | US | disclosed |
| EP-3517538-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | Chugai Seiyaku Kabushiki Kaisha (JP) | 2019-07-31 | — | — | EP | disclosed |
| US-20190225604-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225604-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | DPP4 16/4885DPP7 17/4885DPP8 38/4885 |
| US-20230382912-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | DPP4 16/4885DPP7 17/4885DPP8 38/4885 |
| US-20210017176-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | DPP4 6/4885DPP7 13/4885DPP8 17/4885 |
| US-11814381-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | GLP1R, GPR119, GIPR | DPP4 6/4885DPP7 12/4885DPP8 17/4885 |
| US-10858356-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | GLP1R, GPR119, GIPR | DPP4 16/4885DPP7 17/4885DPP8 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.